(2015) Multidrug-resistant tuberculosis in Europe, 2010–2011. Emerging Infectious Diseases , Volume 21 (Number 3). pp. 409-416. doi:10.3201/eid2103.141343

Research output not available from this repository, contact author.

Request Changes to record.

Abstract

Drug-resistant Mycobacterium tuberculosis is challenging elimination of tuberculosis (TB). We evaluated risk factors for TB and levels of second-line drug resistance in M. tuberculosis in patients in Europe with multidrug-resistant (MDR) TB. A total of 380 patients with MDR TB and 376 patients with non–MDR TB were enrolled at 23 centers in 16 countries in Europe during 2010–2011. A total of 52.4% of MDR TB patients had never been treated for TB, which suggests primary transmission of MDR M. tuberculosis. At initiation of treatment for MDR TB, 59.7% of M. tuberculosis strains tested were resistant to pyrazinamide, 51.1% were resistant to ≥1 second-line drug, 26.6% were resistant to second-line injectable drugs, 17.6% were resistant to fluoroquinolones, and 6.8% were extensively drug resistant. Previous treatment for TB was the strongest risk factor for MDR TB. High levels of primary transmission and advanced resistance to second-line drugs characterize MDR TB cases in Europe.

Item Type:	Journal Article
Divisions:	Faculty of Medicine > Warwick Medical School > Biomedical Sciences > Microbiology & Infection Faculty of Medicine > Warwick Medical School > Biomedical Sciences > Translational & Experimental Medicine Faculty of Medicine > Warwick Medical School
Journal or Publication Title:	Emerging Infectious Diseases
Publisher:	US Department of Health and Human Services
ISSN:	1080-6059
Official Date:	March 2015
Dates:	Date Event March 2015 Published
Volume:	Volume 21
Number:	Number 3
Page Range:	pp. 409-416
DOI:	10.3201/eid2103.141343
Status:	Peer Reviewed
Publication Status:	Published
Access rights to Published version:	Open Access

Request changes or add full text files to a record

Repository staff actions (login required)

View Item